3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Endometrial Neoplasms
7
Ovarian Neoplasms
6
Neoplasms
6
Uterine Cervical Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
3
Rectal Neoplasms
3
Pancreatic Neoplasms
3
Neoplasm Metastasis
3
Head and Neck Neoplasms
3
Colonic Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Breast Neoplasms
3
Triple Negative Breast Neoplasms
2
Lung Neoplasms
2
Fallopian Tube Neoplasms
2
Carcinoma, Neuroendocrine
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Turcot syndrome
1
Small Cell Lung Carcinoma
1
Sarcoma, Clear Cell
1
Sarcoma
1
Recurrence
1
Penile Neoplasms
1
Pathologic Complete Response
1
Neoplasms, Second Primary
1
Mesothelioma, Malignant
1
Mesothelioma
1
Melanoma
1
MMRd/MSI-H Stage II-III Endometrial Cancer
1
Interventions
Radiotherapy
4
fludarabine phosphate
2
aldesleukin
2
Paclitaxel
2
Nivolumab
2
Bevacizumab
2
zimberelimab
1
rocakinogene sifuplasmid
1
liposomal doxorubicin
1
fludarabine
1
durvalumab
1
dostarlimab
1
belzutifan
1
alovudine
1
Watchful Waiting
1
Vaccines, Synthetic
1
VGX-3100
1
Therapeutic Touch
1
Specimen Handling
1
Ritonavir
1
Radiosurgery
1
Radiation
1
Peripheral Blood Stem Cell Transplantation
1
Papillomavirus Vaccines
1
Observation
1
Mycophenolic Acid
1
Magnetic Resonance Spectroscopy
1
MEDI0457
1
Ipilimumab
1
Indinavir
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Vaginal Neoplasms
×
dostarlimab
×
Clear all
NCT06023862
2026-05-06
DOVE
Yonsei University
Phase 2
Recruiting
198 enrolled